Routine employee warrant grant with no immediate catalyst. Monitor upcoming earnings for pipeline updates on TransCon products, which drive valuation.
Price Chart
Executive Summary
Ascendis Pharma filed its updated Articles of Association on Form 6-K, reflecting the grant of 35,890 warrants to employees on October 13, 2026, at an exercise price of $223.21 per share. The filing also confirms that 4,613,777 warrants remain outstanding and 1,459,173 warrants are available for future grant. This is a routine administrative update with no material financial impact.
Key Facts
- Board granted 35,890 warrants to employees on October 13, 2026, at $223.21 per share.
- Warrants vest 25% after one year, then 1/36th monthly for remaining 75%.
- Total outstanding warrants under articles 4a, 4f, 4g, 4h, and 4i: 4,613,777.
- Warrants for 1,459,173 shares remain available for future grant.
- Share capital is DKK 66,400,738 divided into shares of DKK 1 each.
- Articles updated to reflect direct listing of shares (no longer via ADSs).
Financial Impact
No financial figures reported; routine warrant grant with immaterial dilution (35,890 shares vs. 66.4M shares outstanding).
Risk Factors
- Potential future dilution from outstanding warrants (4.6M) and available grants (1.5M).
- No financial data or guidance provided in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-421789 |
| Document: d743945d6k.htm | 0001193125-26-421789 |
| Document: 0001193125-26-421789-index-headers.html | 0001193125-26-421789 |
| Document: 0001193125-26-421789-index.html | 0001193125-26-421789 |
| Document: 0001193125-26-421789.txt | 0001193125-26-421789 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 2d ago | 6-K | $245.85 $249.55 | ▲ +1.50% | ▲ +1.16% | $249.55 (+1.50%) |
Oct 16, 2026 12d ago | 6-K | $225.25 $229.95 | ▲ +2.09% | ▲ +1.66% | $249.55 (+10.79%) |
Oct 14, 2026 14d ago | 6-K | $226.62 $225.25 | ▼ −0.60% | ▲ +0.50% | $249.55 (+10.12%) |
Sep 22, 2026 5w ago | Institutional Cluster | $237.57 $223.13 | ▲ +6.08% | ▲ +5.36% | $249.55 (−5.04%) |
Sep 9, 2026 7w ago | Insider Cluster | $261.23 $263.52 | ▲ +0.87% | ▲ +0.02% | $249.55 (−4.47%) |
Aug 31, 2026 8w ago | 6-K | $260.25 $267.31 | ▲ +2.71% | ▲ +2.27% | $249.55 (−4.11%) |
Aug 27, 2026 8w ago | ANALYST-UPGRADE | $249.36 $247.91 | ▼ −0.58% | ▼ −0.35% | $249.55 (+0.08%) |
Aug 19, 2026 10w ago | ANALYST-UPGRADE | $259.62 $254.81 | ▼ −1.85% | ▼ −1.01% | $249.55 (−3.88%) |
Aug 18, 2026 10w ago | Insider Buy | $259.62 $254.81 | ▼ −1.85% | ▼ −1.01% | $249.55 (−3.88%) |
Aug 13, 2026 10w ago | 6-K | $246.23 $248.50 | ▲ +0.92% | ▲ +1.12% | $249.55 (+1.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers